Core Laboratories Total Revenue Over Time
| CLB Stock | USD 21.28 0.16 0.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Core Laboratories Performance and Core Laboratories Correlation. Core |
Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.316 | Dividend Share 0.04 | Earnings Share 0.54 | Revenue Per Share 11.158 | Quarterly Revenue Growth 0.072 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Revenue Analysis
Compare Core Laboratories and related stocks such as Bristow Group, RPC Inc, and NOV Inc Total Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VTOL | 1.4 B | 1.4 B | 272.9 M | 299 M | 331.2 M | 281.8 M | 247.2 M | 231.3 M | 221.7 M | 226.1 M | 1.2 B | 1.2 B | 1.2 B | 1.3 B | 708.4 M |
| RES | 61.8 M | 1.8 B | 1.9 B | 1.9 B | 2.3 B | 1.3 B | 729 M | 1.6 B | 1.7 B | 1.2 B | 598.3 M | 864.9 M | 1.6 B | 1.6 B | 1.7 B |
| NOV | 648.6 M | 14.7 B | 20 B | 22.8 B | 21.4 B | 14.8 B | 7.3 B | 7.3 B | 8.5 B | 8.5 B | 6.1 B | 5.5 B | 7.2 B | 8.6 B | 8.8 B |
| OII | 119.9 M | 2.2 B | 2.8 B | 3.3 B | 3.7 B | 3.1 B | 2.3 B | 1.9 B | 1.9 B | 2 B | 1.8 B | 1.9 B | 2.1 B | 2.4 B | 1.3 B |
| WHD | 221.4 M | 221.4 M | 221.4 M | 221.4 M | 221.4 M | 221.4 M | 155 M | 341.2 M | 544.1 M | 628.4 M | 348.6 M | 438.6 M | 688.4 M | 1.1 B | 1.2 B |
| DNOW | 3.4 B | 3.4 B | 3.4 B | 4.3 B | 4.1 B | 3 B | 2.1 B | 2.6 B | 3.1 B | 3 B | 1.6 B | 1.6 B | 2.1 B | 2.3 B | 2.2 B |
| OIS | 359 M | 3.5 B | 4.4 B | 2.7 B | 1.8 B | 1.1 B | 694.4 M | 670.6 M | 1.1 B | 1 B | 638.1 M | 573.2 M | 737.7 M | 782.3 M | 1.5 B |
| GEOS | 41 M | 191.7 M | 300.6 M | 236.9 M | 84.9 M | 62.1 M | 73.7 M | 75.7 M | 95.8 M | 87.8 M | 94.9 M | 89.3 M | 124.5 M | 143.2 M | 115.2 M |
| NR | 37.7 M | 958.2 M | 1 B | 1.1 B | 1.1 B | 676.9 M | 471.5 M | 747.8 M | 946.5 M | 820.1 M | 492.6 M | 614.8 M | 815.6 M | 749.6 M | 549.7 M |
| MRC | 1.7 B | 4.8 B | 5.6 B | 5.2 B | 5.9 B | 4.5 B | 3 B | 3.6 B | 4.2 B | 3.7 B | 2.6 B | 2.7 B | 3.4 B | 3.4 B | 3 B |
| NOA | 181.2 M | 1 B | 544.6 M | 470.5 M | 471.8 M | 281.3 M | 213.2 M | 292.6 M | 410.1 M | 719.1 M | 500.4 M | 654.1 M | 769.5 M | 957.2 M | 605 M |
| NGS | 8.8 M | 65.2 M | 93.7 M | 89.2 M | 97 M | 95.9 M | 71.7 M | 67.7 M | 65.5 M | 78.4 M | 68.1 M | 72.4 M | 84.8 M | 121.2 M | 72.2 M |
| CHX | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 751.3 M | 1 B | 1.2 B | 1.1 B | 1.9 B | 3.1 B | 3.8 B | 3.8 B | 2.2 B |
| EFXT | 1.8 B | 1.2 B | 1.5 B | 1.4 B | 1.8 B | 1.6 B | 1.1 B | 1.6 B | 1.7 B | 2 B | 1.2 B | 960.2 M | 1.8 B | 3.2 B | 1.9 B |
Core Laboratories and related stocks such as Bristow Group, RPC Inc, and NOV Inc Total Revenue description
Total revenue comprises all receipts Core Laboratories generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.My Equities
My Current Equities and Potential Positions
| Core Laboratories NV | CLB |
| Classification | Petroleum and Natural Gas |
| Location | Netherlands |
| Exchange | New York Stock Exchange |
USD 21.28
Check out Core Laboratories Performance and Core Laboratories Correlation. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Core Laboratories technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.